Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study is to determine the Regorafenib Dose (RD) for the phase II trial of Regorafenib
administered in combination with mGEMOX in patients with advanced biliary tract cancer.